Although TNBC is a heterogeneous disease [48], it is well known that the major components of the uPA system including uPA, uPAR and PAI-1 are often overexpressed in this BC subtype and may be interesting candidates for targeted therapies [9]. The gene discussed is PLAU; the disease is breast cancer.